IL208808A - Antibodies against a17-il homo-dimeric, il-17f homo-dimeric and against the hetero-dimeric complex il-17a / il-17f and their use - Google Patents

Antibodies against a17-il homo-dimeric, il-17f homo-dimeric and against the hetero-dimeric complex il-17a / il-17f and their use

Info

Publication number
IL208808A
IL208808A IL208808A IL20880810A IL208808A IL 208808 A IL208808 A IL 208808A IL 208808 A IL208808 A IL 208808A IL 20880810 A IL20880810 A IL 20880810A IL 208808 A IL208808 A IL 208808A
Authority
IL
Israel
Prior art keywords
homodimer
antibodies
heterodimeric complex
heterodimeric
complex
Prior art date
Application number
IL208808A
Other languages
English (en)
Hebrew (he)
Other versions
IL208808A0 (en
Original Assignee
Novimmune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41265089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL208808(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novimmune Sa filed Critical Novimmune Sa
Publication of IL208808A0 publication Critical patent/IL208808A0/en
Publication of IL208808A publication Critical patent/IL208808A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL208808A 2008-05-05 2010-10-19 Antibodies against a17-il homo-dimeric, il-17f homo-dimeric and against the hetero-dimeric complex il-17a / il-17f and their use IL208808A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12646508P 2008-05-05 2008-05-05
US9836908P 2008-09-19 2008-09-19
PCT/IB2009/005796 WO2009136286A2 (en) 2008-05-05 2009-05-05 Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof

Publications (2)

Publication Number Publication Date
IL208808A0 IL208808A0 (en) 2011-01-31
IL208808A true IL208808A (en) 2015-04-30

Family

ID=41265089

Family Applications (2)

Application Number Title Priority Date Filing Date
IL208808A IL208808A (en) 2008-05-05 2010-10-19 Antibodies against a17-il homo-dimeric, il-17f homo-dimeric and against the hetero-dimeric complex il-17a / il-17f and their use
IL238051A IL238051A0 (en) 2008-05-05 2015-03-31 Antibodies active against il-17a/il-17f and methods of using them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL238051A IL238051A0 (en) 2008-05-05 2015-03-31 Antibodies active against il-17a/il-17f and methods of using them

Country Status (19)

Country Link
US (4) US20090317400A1 (enExample)
EP (1) EP2288382B1 (enExample)
JP (4) JP2011519911A (enExample)
KR (5) KR101711798B1 (enExample)
CN (2) CN102083858B (enExample)
AU (1) AU2009245440C1 (enExample)
BR (1) BRPI0908312A2 (enExample)
CA (1) CA2721713C (enExample)
CO (1) CO6351800A2 (enExample)
EC (1) ECSP10010653A (enExample)
HK (1) HK1210484A1 (enExample)
IL (2) IL208808A (enExample)
MA (1) MA32365B1 (enExample)
MX (2) MX355256B (enExample)
NZ (3) NZ588674A (enExample)
RU (2) RU2474588C2 (enExample)
SG (2) SG190626A1 (enExample)
WO (1) WO2009136286A2 (enExample)
ZA (1) ZA201007452B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2784084B2 (en) 2003-07-08 2023-10-04 Novartis Pharma AG Antagonist antibodies to IL-17A/F heterologous polypeptides
WO2009030239A1 (en) * 2007-09-06 2009-03-12 Genmab A/S Novel methods and antibodies for treating cancer
SG190626A1 (en) 2008-05-05 2013-06-28 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
CN102458437B (zh) * 2009-05-05 2015-06-10 诺维莫尼公司 抗il-17f抗体及其使用方法
US8911722B2 (en) 2009-09-14 2014-12-16 The Regents Of The University Of Colorado, A Body Corporate Modulation of yeast-based immunotherapy products and responses
DK2519542T3 (en) * 2009-12-28 2019-01-14 Onco Therapy Science Inc ANTI-CDH3 ANTIBODIES AND APPLICATIONS THEREOF.
US20110250206A1 (en) * 2010-02-11 2011-10-13 Axtell Robert C Markers for determination of patient responsiveness
WO2011140484A1 (en) * 2010-05-06 2011-11-10 Singulex, Inc Methods for diagnosing, staging, predicting risk for developing and identifying treatment responders for rheumatoid arthritis
EP2571901B1 (en) 2010-05-20 2019-01-02 Ablynx N.V. Biological materials related to her3
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
PT2663577T (pt) 2011-01-14 2017-07-19 Ucb Biopharma Sprl Anticorpo de ligação a il-17a e il-17f
EP2673287B1 (de) 2011-02-08 2017-08-30 Merck Patent GmbH Aminostatin-derivate zur behandlung von arthrose
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US9475872B2 (en) * 2011-12-28 2016-10-25 Immunoqure Ag Nucleic acid molecules encoding moonoclonal antibodies speceific for IL17F
US10131709B2 (en) 2011-12-28 2018-11-20 Immunoqure Ag Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
SI2852615T1 (sl) 2012-05-22 2019-02-28 Bristol-Myers Squibb Company IL-17A/F IL-23 bispecifična protitelesa in njihova uporaba
WO2014001368A1 (en) * 2012-06-25 2014-01-03 Orega Biotech Il-17 antagonist antibodies
IL244149B2 (en) 2013-09-13 2025-09-01 Genentech Inc Methods and compositions containing purified recombinant polypeptides
CA3174012A1 (en) 2013-09-13 2015-03-19 Genentech, Inc. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
EP3072905B1 (en) * 2013-11-18 2020-08-19 Shanghai Hengrui Pharmaceutical Co., Ltd. Il-17a binding agent and uses thereof
WO2015127405A2 (en) 2014-02-21 2015-08-27 Genentech, Inc. Anti-il-13/il-17 bispecific antibodies and uses thereof
EP3212665A2 (en) * 2014-10-31 2017-09-06 F. Hoffmann-La Roche AG Anti-il-17a and il-17f cross reactive antibody variants and compositions comprising and methods of making and using same
CA2966573A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Methods of producing two chain proteins in bacteria
WO2016073791A1 (en) * 2014-11-05 2016-05-12 Genentech, Inc. Methods of producing two chain proteins in bacteria
HRP20240959T1 (hr) 2014-11-20 2024-10-25 F. Hoffmann - La Roche Ag Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t stanice i antagonistom vezivanja osi pd-1
KR20170089013A (ko) * 2014-12-15 2017-08-02 모르포시스 아게 Il-17c에 대한 항체
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CN107407677B (zh) 2015-01-28 2020-07-17 豪夫迈·罗氏有限公司 多发性硬化的基因表达标志和治疗
AR103935A1 (es) * 2015-03-16 2017-06-14 Genentech Inc Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th-2
AU2016278040B2 (en) 2015-06-16 2019-07-04 Nanophagix LLC Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
CN108290927B (zh) * 2015-07-15 2022-06-24 加州理工学院 Il-17f-特异性捕获剂、组合物以及使用和制造的方法
EP3337819B1 (en) * 2015-08-20 2024-02-21 F. Hoffmann-La Roche AG Method of purifying for producing recombinant polypeptides using fkpa
AU2016312909B2 (en) 2015-08-21 2022-12-08 F. Hoffmann-La Roche Ag Method for the reduction of host cell proteins in affinity chromatography
US11492396B2 (en) * 2015-10-27 2022-11-08 UCB Biopharma SRL Methods of treatment using anti-IL-17A/F antibodies
GB201522391D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules
RU2680011C2 (ru) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
CN107488227A (zh) * 2016-06-12 2017-12-19 三生国健药业（上海）股份有限公司 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
WO2018050028A1 (zh) 2016-09-14 2018-03-22 北京韩美药品有限公司 一种能够特异性地结合il-17a的抗体及其功能片段
AR110873A1 (es) 2017-02-10 2019-05-08 Genentech Inc Anticuerpos contra triptasa, composiciones de estos y usos de estos
KR102321861B1 (ko) * 2017-03-10 2021-11-05 쑤저우 카노바 바이오파마슈티컬 컴퍼니 리미티드 Il-17a 및 il-17f 모두에 대한 단일클론 항체 및 이의 용도
RU2020117362A (ru) 2017-11-02 2021-12-02 Новартис Аг Способы лечения тендинопатии с помощью антагонистов интерлейкина-17 (il-17)
US11161900B2 (en) * 2018-12-13 2021-11-02 Argenx Bvba Antibodies that specifically bind to human complement factor C2b
WO2020156539A1 (en) * 2019-02-02 2020-08-06 Huahui Health Ltd. Anti-fgf19 antibodies
CA3181418A1 (en) * 2020-04-30 2021-11-04 Janssen Pharmaceutica Nv Methods of identifying modulators of the il-17 pathway
CN118103070A (zh) * 2021-08-09 2024-05-28 默克专利有限公司 解偶联t细胞介导的肿瘤细胞毒性与促炎细胞因子释放的蛋白质
CA3253618A1 (en) 2022-05-16 2023-11-23 Novartis Ag METHODS FOR TREATMENT OF GIANT CELL ARTERITIS USING INTERLEUKIN-17 (IL-17) ANTAGONISTS
EP4525914A1 (en) 2022-05-18 2025-03-26 Novartis AG Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists
EP4393948A1 (en) * 2022-12-28 2024-07-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Therapeutic vhh antibodies cross-neutralizing the il-17a and il-17f homodimers as well as the il-17af heterodimer
WO2025202213A1 (en) 2024-03-26 2025-10-02 Institut National de la Santé et de la Recherche Médicale Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4738681A (en) * 1985-07-10 1988-04-19 Harrington Arthritis Research Center Femoral-joint prosthetic device
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5370870A (en) * 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
SE500903C2 (sv) 1989-12-20 1994-09-26 Atlas Copco Constr & Mining Bergborrningsrigg
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5364839A (en) 1990-06-18 1994-11-15 Genetics Institute, Inc. Osteoinductive pharmaceutical formulations
US5206023A (en) 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5273033A (en) * 1991-09-19 1993-12-28 Murray Electronics Associates Limited Partnership Electrical stimulation for treatment of osteoarthritis
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
GB9214857D0 (en) 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
US5536637A (en) * 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
US6274711B1 (en) 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US5444047A (en) * 1994-06-16 1995-08-22 Dipasquale; Gene Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I
WO2000073452A2 (en) 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
MX9707021A (es) 1995-03-23 1997-11-29 Immunex Corp Receptor de il-7.
US5573762A (en) * 1995-04-24 1996-11-12 Genentech, Inc. Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
US6074849A (en) * 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
CA2227220A1 (en) 1995-07-19 1997-02-06 Genetics Institute, Inc. Human ctla-8 and uses of ctla-8-related proteins
US6902735B1 (en) 1995-07-19 2005-06-07 Genetics Institute, Llc Antibodies to human IL-17F and other CTLA-8-related proteins
WO1997020062A1 (en) 1995-12-01 1997-06-05 University Of Massachusetts Il-12 p40 subunit fusion polypeptides and uses thereof
EP1876241A3 (en) 1996-01-11 2008-07-30 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
ES2326347T3 (es) * 1996-11-27 2009-10-07 Immunex Corporation Metodo para regular la produccion de oxido nitrico.
US6054559A (en) * 1997-01-28 2000-04-25 Smithkline Beecham Corporation Interleukin-1 receptor antagonist beta (IL-1raβ)
US20020177188A1 (en) * 1998-05-15 2002-11-28 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
WO2000070050A1 (en) 1999-05-14 2000-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US6579520B2 (en) * 1998-05-15 2003-06-17 Genentech, Inc. IL-17 related mammalian cytokine polypeptides (IL-17E)
US6569645B2 (en) * 1999-05-14 2003-05-27 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
CA2288360A1 (en) 1997-04-25 1998-11-05 Zymogenetics, Inc. Mammalian cytokine-like factor 7
EP1012260A4 (en) 1997-07-16 2001-05-09 Human Genome Sciences Inc INTERLEUKINE-20
US6060284A (en) * 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
PE20000183A1 (es) 1997-07-25 2000-03-11 Schering Corp Citoquinas de mamiferos y reactivos relacionados
DE69841140D1 (de) 1997-09-17 2009-10-22 Human Genome Sciences Inc Interleukin-17 rezeptor-ähnliches protein
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
US6562578B1 (en) * 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
WO1999032632A1 (en) 1997-12-19 1999-07-01 Millennium Pharmaceuticals, Inc. Novel embryo-derived interleukin related factor molecules and uses therefor
EP1040196A2 (en) 1997-12-19 2000-10-04 American Home Products Corporation Transgenic animal model for degenerative diseases of cartilage
WO1999035267A1 (en) 1998-01-09 1999-07-15 Immunex Corporation Human and murine il-17d, cytokine related to interleukin-17: dna and polypeptides
PT1490386E (pt) 1998-03-10 2008-11-24 Genentech Inc Novos polipéptidos e ácidos nucleicos que os codificam
DE69931284T9 (de) 1998-03-25 2007-10-18 Genentech Inc., San Francisco Menschliches Neurotrimin-Homolog
CA2323929C (en) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
ATE474849T1 (de) * 1998-04-14 2010-08-15 Chugai Pharmaceutical Co Ltd Neues cytokinartiges protein
JP3577586B2 (ja) 1998-05-15 2004-10-13 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療用途
US7771719B1 (en) * 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
EP1443055A3 (en) 1998-05-29 2005-06-08 Human Genome Sciences, Inc. Interleukins-21 and 22
US20010023070A1 (en) 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
JP2002516103A (ja) 1998-05-29 2002-06-04 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド インターロイキン２１およびインターロイキン２２
WO2000015798A2 (en) 1998-09-17 2000-03-23 Zymogenetics, Inc. Mammalian transforming growth factor beta - 9 (ztgfss9)
AU6277799A (en) 1998-10-02 2000-04-26 Eli Lilly And Company Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and usesthereof
JP2000186046A (ja) 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
WO2001054477A2 (en) 2000-01-25 2001-08-02 Hyseq, Inc. Novel nucleic acids and polypeptides
ATE444365T1 (de) 1999-01-11 2009-10-15 Schering Corp Interleukin-17 verwandte zytokine aus säugetieren. dafür kodierende polynukleotide. verwendungen
AR022237A1 (es) 1999-01-11 2002-09-04 Schering Corp Citoquinas mamiferas purificadas; reactivos y metodos relacionados
AU2596700A (en) 1999-03-08 2000-09-28 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
CN101333256A (zh) 1999-03-25 2008-12-31 艾博特股份有限两合公司 结合人il-12的人抗体及其生产方法
US20030082734A1 (en) * 1999-06-01 2003-05-01 Dowling Lynette M. Mammalian receptor proteins; related reagents and methods
US20030199041A1 (en) * 1999-07-07 2003-10-23 Presnell Scott R. Interleukin-17 receptor homologue
DK1190056T3 (da) 1999-07-07 2007-07-30 Zymogenetics Inc Human cytokin receptor
AU7680300A (en) 1999-08-18 2001-03-13 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Human dna sequences
AU7573000A (en) 1999-09-01 2001-03-26 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU7099200A (en) 1999-09-03 2001-04-10 Human Genome Sciences, Inc. 52 human secreted proteins
EP1221482B1 (en) * 1999-09-27 2005-12-28 Chugai Seiyaku Kabushiki Kaisha Hemopoietin receptor protein, nr12
EP1234036A2 (en) 1999-11-30 2002-08-28 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20040043397A1 (en) * 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
ATE519847T1 (de) 1999-12-23 2011-08-15 Genentech Inc Il-17-homologe polypeptide und ihre therapeutische verwendung
US6380362B1 (en) 1999-12-23 2002-04-30 Genesis Research & Development Corporation Ltd. Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use
WO2001049728A2 (en) 2000-01-06 2001-07-12 Protegene Inc. HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
AU2001236638A1 (en) 2000-02-04 2001-08-14 The Board Of Trustees Of The University Of Arkansas Evi27 gene sequences and protein encoded thereby
AU6802801A (en) 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
MXPA02009055A (es) 2000-03-16 2003-03-12 Amgen Inc Receptor il-17 como moleculas y usos de los mismos.
US7094566B2 (en) * 2000-03-16 2006-08-22 Amgen Inc., IL-17 receptor like molecules and uses thereof
TWI322154B (en) 2000-03-16 2010-03-21 Amgen Inc Il-17 receptor like molecules and uses thereof
DK1265630T3 (da) * 2000-03-24 2006-10-09 Genentech Inc Anvendelse af insulin til behandling af brusksygdomme
US6479636B1 (en) 2000-04-11 2002-11-12 Honiron Corporation (A Louisiana Corporation) Sugarcane fractioning system
SI1274450T1 (sl) 2000-04-18 2009-04-30 Schering Corp Medicinske uporabe agonistov in antagonistov IL-174
US7422743B2 (en) * 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
PL209128B1 (pl) 2000-05-10 2011-07-29 Schering Corp Białko receptora spokrewnionego z receptorami cytokin oraz związane z nim produkty, sposoby i zastosowania
US20030092881A1 (en) 2000-05-24 2003-05-15 Gorman Daniel M. Mammalian receptor proteins; related reagents and methods
US20030096969A1 (en) * 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
MXPA02012743A (es) 2000-06-22 2003-04-25 Amgen Inc Moleculas tipo il-17 y usos de las mismas.
EP1309620A2 (en) 2000-06-23 2003-05-14 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
JP2004516013A (ja) 2000-07-20 2004-06-03 ジェネンテック・インコーポレーテッド 血管形成に関連する障害を診断及び治療するための組成物と方法
EP1354040A2 (en) 2000-07-20 2003-10-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002008259A2 (en) 2000-07-26 2002-01-31 Zymogenetics, Inc. Human cytokine receptor
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
JP2002139499A (ja) * 2000-08-23 2002-05-17 Sanyo Electric Co Ltd 化学物質センサおよび化学物質の検出方法
JP2002076897A (ja) * 2000-08-29 2002-03-15 Toshiba Corp Ｄａコンバータ
AU2001296229A1 (en) 2000-10-13 2002-04-29 Eli Lilly And Company Methods of using a human il-17-related polypeptide to treat disease
GB2372464B (en) 2001-02-22 2003-05-14 Vivascience Ltd Method of isolating a charged compound
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
WO2003014309A2 (en) * 2001-08-07 2003-02-20 Immunex Corporation Interleukin-1 receptors in the treatment of diseases
JP2005506342A (ja) 2001-10-15 2005-03-03 ジェネンテック・インコーポレーテッド インスリン耐性状態の治療及び診断
US7103929B2 (en) * 2002-03-12 2006-09-12 Little Rapids Corporation Disposable bedding with absorbent region
KR101053412B1 (ko) * 2002-10-30 2011-08-01 제넨테크, 인크. Ｉｌ―１７ 생성의 억제
BRPI0408247A (pt) * 2003-03-10 2006-03-01 Schering Corp usos de antagonistas e agonistas de il-23 e reagentes relacionados
MXPA05013881A (es) 2003-06-23 2008-02-13 Genetics Inst Llc Anticuerpos contra interleucina-22 y usos de los mismos.
EP2784084B2 (en) 2003-07-08 2023-10-04 Novartis Pharma AG Antagonist antibodies to IL-17A/F heterologous polypeptides
TWI344364B (en) * 2003-11-10 2011-07-01 Synta Pharmaceuticals Corp Fused heterocyclic compounds
JP2007510747A (ja) * 2003-11-10 2007-04-26 シンタ ファーマシューティカルズ コーポレーション ピリジン化合物
AU2004289305A1 (en) 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Heteroaryl-Hydrazone compounds
ATE395083T1 (de) 2003-11-21 2008-05-15 Ucb Pharma Sa Verfahren zur behandlung von multipler sklerose durch hemmung der il-17-aktivität
WO2005079837A1 (en) * 2004-02-17 2005-09-01 Schering Corporation Methods of modulating il-23 activity; related reagents
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
US7501247B2 (en) 2004-05-03 2009-03-10 Schering Corporation Method of treating skin inflammation
CN101001871A (zh) * 2004-06-10 2007-07-18 津莫吉尼蒂克斯公司 可溶性ZcytoR14、抗ZcytoR14抗体和结合伴侣以及在炎症中的使用方法
US7629691B2 (en) 2004-06-16 2009-12-08 Honeywell International Inc. Conductor geometry for electronic circuits fabricated on flexible substrates
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
AR051444A1 (es) * 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
JP2008523083A (ja) 2004-12-08 2008-07-03 イムノメディクス， インコーポレイテッド 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物
CA2596509A1 (en) * 2005-02-14 2006-08-24 Wyeth Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor
US7858843B2 (en) 2005-06-06 2010-12-28 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
WO2007027761A2 (en) 2005-09-01 2007-03-08 Schering Corporation Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
US20070249533A1 (en) 2005-09-28 2007-10-25 Levin Steven D Il-17a and il-17f antagonists and methods of using the same
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
CN101326195B9 (zh) 2005-12-13 2022-11-11 伊莱利利公司 抗il-17抗体
WO2007081988A2 (en) * 2006-01-11 2007-07-19 Aurora Specialty Chemistries Corp. Stable dispersion of dbnpa in viscosified brine
AU2007235199B8 (en) 2006-01-31 2010-10-28 Novartis Ag IL-17 antagonistic antibodies for treating cancer
WO2007106769A2 (en) * 2006-03-10 2007-09-20 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
US7790163B2 (en) 2006-03-10 2010-09-07 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
AU2007260787A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc IL-17 and IL-23 antagonists and methods of using the same
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
CA2679588A1 (en) 2007-03-26 2008-10-02 Zymogenetics, Inc. Soluble il-17ra/rc fusion proteins and related methods
EP2392597B1 (en) 2007-04-27 2014-04-02 ZymoGenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
CA2682889C (en) * 2007-04-27 2016-04-05 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
AU2008266745B2 (en) 2007-06-20 2014-04-17 Merck Sharp & Dohme Corp. Joint destruction biomarkers for anti-IL-17A therapy of inflammatory joint disease
EP2182943B1 (en) 2007-07-23 2016-10-26 Janssen Biotech, Inc. Methods and compositions for treating fibrosis related disorders using il-17 antagonists
WO2009026412A1 (en) 2007-08-21 2009-02-26 Children's Medical Center Corporation Treatment of airway hyperreactivity
GB0807413D0 (en) * 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
SG190626A1 (en) 2008-05-05 2013-06-28 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
SG174891A1 (en) 2009-04-01 2011-11-28 Genentech Inc Treatment of insulin-resistant disorders
CN102458437B (zh) 2009-05-05 2015-06-10 诺维莫尼公司 抗il-17f抗体及其使用方法

Also Published As

Publication number Publication date
KR101711798B1 (ko) 2017-03-02
JP5898653B2 (ja) 2016-04-06
CN102083858B (zh) 2015-01-14
CO6351800A2 (es) 2011-12-20
SG190626A1 (en) 2013-06-28
US20130195872A1 (en) 2013-08-01
NZ600584A (en) 2014-05-30
US20090317400A1 (en) 2009-12-24
BRPI0908312A2 (pt) 2015-08-18
ECSP10010653A (es) 2011-02-28
IL238051A0 (en) 2015-05-31
JP2011519911A (ja) 2011-07-14
JP2017048191A (ja) 2017-03-09
JP2014001217A (ja) 2014-01-09
WO2009136286A2 (en) 2009-11-12
EP2288382B1 (en) 2018-08-29
CN104628855A (zh) 2015-05-20
US9650437B2 (en) 2017-05-16
JP6507133B2 (ja) 2019-04-24
MX2010012090A (es) 2011-04-11
MA32365B1 (fr) 2011-06-01
SG10201608871XA (en) 2016-12-29
IL208808A0 (en) 2011-01-31
CA2721713A1 (en) 2009-11-12
KR101508086B1 (ko) 2015-04-07
KR20160028505A (ko) 2016-03-11
US8771697B2 (en) 2014-07-08
RU2010149746A (ru) 2012-06-20
ZA201007452B (en) 2012-01-25
KR20110025649A (ko) 2011-03-10
KR20130138354A (ko) 2013-12-18
RU2012151478A (ru) 2014-06-10
CN102083858A (zh) 2011-06-01
KR20170023209A (ko) 2017-03-02
KR20150002874A (ko) 2015-01-07
US20120269820A1 (en) 2012-10-25
US20120141492A1 (en) 2012-06-07
NZ623706A (en) 2015-12-24
WO2009136286A3 (en) 2010-06-10
NZ588674A (en) 2013-02-22
HK1210484A1 (en) 2016-04-22
AU2009245440C1 (en) 2013-03-14
WO2009136286A9 (en) 2010-04-22
MX355256B (es) 2018-04-11
JP2015166355A (ja) 2015-09-24
US8715669B2 (en) 2014-05-06
AU2009245440B2 (en) 2012-08-02
CA2721713C (en) 2019-07-09
EP2288382A2 (en) 2011-03-02
RU2474588C2 (ru) 2013-02-10
AU2009245440A1 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
IL208808A (en) Antibodies against a17-il homo-dimeric, il-17f homo-dimeric and against the hetero-dimeric complex il-17a / il-17f and their use
IL196968A0 (en) Antibodies to il-17a
IL232276A0 (en) Antibodies to 6-il and their uses
IL257290A (en) Antibodies to il 6 and their use
PL2294083T3 (pl) Epitopy il-17a i il-17f i specyficzne względem nich przeciwciała
IL201281A0 (en) Antibodies that bind both il - 17a and il-17f and methods of using the same
IL193444A0 (en) Antibodies that bind both il-17a and il-17f and methods of using the same
ZA201101047B (en) Antibodies to ccr2
LT2663577T (lt) Antikūnas, surišantis il-17a ir il-17f
IL235877B (en) Antibodies to 6-il and their use
IL224752A (en) METHOD OF USING IL-α1 ANTIBODIES
IL232008A0 (en) Alpha-4-beta-7 heterodimeric specific antagonist antibody
IL211087A0 (en) Engineered anti-il-13 antibodies, compositions, methods and uses
EP2125890A4 (en) ANTIBODIES AGAINST PHOSPHORYLATED IRAQ4
ZA201100261B (en) Anti-hepcidin-25 selective antibodies and uses thereof
ITMO20070024A1 (it) Preforma per ottenere contenitori
HK1125390A (en) Antibodies to il-17a
AU2008904182A0 (en) Anti-IL-23 heterodimeric specific antibodies
HU0800449D0 (en) Decorative construction brick element for rigid wall-structures built in by adhesive technology, mainly for external wall-cladding without pointing
PH32008000397S1 (en) Philippine national police badge
AU2008904474A0 (en) Social website utility
GB0718834D0 (en) Antibody fusions
GB0718832D0 (en) Antibody fusions

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed